Fresenius Medical Care AG & Co. KGaA (ETR:FME) Given a €53.00 Price Target by Jefferies Financial Group Analysts

Jefferies Financial Group set a €53.00 ($55.79) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) in a research report sent to investors on Tuesday morning, Borsen Zeitung reports.

Other research analysts have also recently issued reports about the stock. Barclays set a €68.00 ($71.58) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, May 31st. Warburg Research set a €62.00 ($65.26) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, May 10th. Deutsche Bank Rese… set a €58.00 ($61.05) target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, May 5th. JPMorgan Chase & Co. set a €51.00 ($53.68) target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday. Finally, Berenberg Bank set a €82.20 ($86.53) target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday.

FME opened at €46.16 ($48.59) on Tuesday. The company has a quick ratio of 0.79, a current ratio of 1.26 and a debt-to-equity ratio of 91.78. The firm has a 50 day moving average price of €56.26 and a 200-day moving average price of €57.49. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €43.53 ($45.82) and a twelve month high of €71.14 ($74.88). The stock has a market capitalization of $13.53 billion and a price-to-earnings ratio of 15.03.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also